FTY720-P, a Biased S1PR Ligand, Increases Mitochondrial Function through STAT3 Activation in Cardiac Cells

Abstract

FTY720 is an FDA-approved sphingosine derivative drug for the treatment of multiple sclerosis. This compound blocks lymphocyte egress from lymphoid organs and autoimmunity through sphingosine 1-phosphate (S1P) receptor blockage. Drug repurposing of FTY720 has revealed improvements in glucose metabolism and metabolic diseases. Studies also demonstrate that preconditioning with this compound preserves the ATP levels during cardiac ischemia in rats. The molecular mechanisms by which FTY720 promotes metabolism are not well understood. Here, we demonstrate that nanomolar concentrations of the phosphorylated form of FTY720 (FTY720-P), the active ligand of S1P receptor (S1PR), activates mitochondrial respiration and the mitochondrial ATP production rate in AC16 human cardiomyocyte cells. Additionally, FTY720-P increases the number of mitochondrial nucleoids, promotes mitochondrial morphology alterations, and induces activation of STAT3, a transcription factor that promotes mitochondrial function. Notably, the effect of FTY720-P on mitochondrial function was suppressed in the presence of a STAT3 inhibitor. In summary, our results suggest that FTY720 promotes the activation of mitochondrial function, in part, through a STAT3 action.

Molecular Mechanisms of Cardiac Development and Disease

“…Using a human cardiomyocyte cell line, the authors demonstrate that FTY720 activates STAT3 which in turn stimulates mitochondrial activation. STAT3 inhibitor treatment reverses this effect, indicating specificity in the beneficial consequences of FTY720 activation on cardiomyocyte mitochondrial function through STAT3 activation [11]. Ariana P. Vargas-Delgado and co-authors discuss in their review for this Special Issue the metabolic impact of Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) on the cardiovascular system.…”